| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NeoGenomics, Inc.$10.76
+0.26 (+2.48%)
D 33Pipeline Score Diagnostics · Commercial
Market Cap
998.26 M
EPS
-0.84
P/E Ratio
-9.11 $
Value Trade
13.00 M
SEC Financials
Q1 2026Dilution Risk
Revenue
186.67 M
R&D Expenses
9.53 M
Operating CF
-8.14 M
Total Assets
1.35 B
Total Liabilities
517.77 M
Equity
828.76 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
146.14 M
Monthly Burn
2.71 M
Runway
52.5 mo
Burn Trend
SEC Filing
Apr 28, 2026
Overview
Volume
9.55 M
52 Week Range
4.72 - 13.74
% held by Insiders
1.88 %
% held by Institutions
106.75 %
Enterprise Value
1.25 B
Total Shares
129.85 M
Short %
6.68 %
Float Shares
127.00 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D33
Pipeline Score $121M
Pipeline ValueValuation Signal
1
Drugs Scored0.4x
rNPV / MCap Top 43%
Micro Cap (rank 517 of 905)
Percentile RankNeoGenomics, Inc. faces pipeline headwinds (33/100), with $302M risk-adjusted pipeline value, led by AZD2936 in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZD2936 Monoclonal antibody | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Phase 2 | NCT05414032 | 14% | $302M | RECRUITING | 102 | - | - | Jul 1, 2028 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NEO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
NEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NEO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
NEO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-NEO
Apr 29, 2026NeoGenomics Reports First Quarter 2026 Results
NeoGenomics reported a strong first quarter for 2026, with total revenue rising 11% year-over-year to $187 million. The company also saw a 14% increase in clinical revenue, driven by a 26% growth in next-generation sequencing (NGS). Additionally, NeoGenomics raised its full-year revenue guidance to between $797 million and $803 million, reflecting confidence in its growth strategy.
Read more →-NEO
Apr 13, 2026NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
NeoGenomics, a leader in oncology diagnostics, will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego. The research emphasizes the importance of combining laboratory testing with clinical data to drive advancements in oncology. CEO Tony Zook highlighted the company's collaborations with biopharma partners, showcasing how these insights can enhance therapy development.
Read more →-NEO
Feb 26, 2026NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics has launched RaDaR ST, a new ctDNA assay for detecting molecular residual disease (MRD) across various solid tumor types. This innovative test aims to provide earlier detection of cancer recurrence, supporting better clinical decisions. The assay is validated through extensive clinical data and is approved by Medicare for initial indications.
Read more →-NEO
Feb 18, 2026NeoGenomics to Participate in Upcoming March 2026 Investor Conferences
NeoGenomics, Inc. has announced its participation in several investor conferences scheduled for March 2026. The company, known for its oncology diagnostic solutions, aims to enhance investor engagement and showcase its innovative services. Live and archived webcasts of the sessions will be available on its Investor Relations website.
Read more →-NEO
Feb 17, 2026NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics reported a strong financial performance for Q4 and full-year 2025, with a 10% increase in revenue to $727 million. The company highlighted significant growth in clinical revenue and successful resolution of patent litigation. However, they also faced a net loss of $108 million for the year, attributed to lower non-clinical revenue and increased operating expenses. Looking ahead, the launch of the RaDaR ST MRD assay is expected to enhance their offerings in the molecular residual disease monitoring market.
Read more →-NEO
Feb 12, 2026NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
NeoGenomics has launched PanTracer Pro, a new testing solution designed to assist clinicians in making informed decisions for patients with advanced-stage solid tumors. This integrated approach aims to streamline the diagnostic process by providing earlier biomarker insights and reducing uncertainty in complex cases. The test offers a turnaround time of 8-10 days, facilitating timely treatment planning.
Read more →-NEO
Jan 27, 2026NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
NeoGenomics, Inc. will announce its fourth quarter and full year 2025 financial results on February 17, 2026. The results will be shared prior to the U.S. market opening, followed by a conference call at 8:30 a.m. ET. The company provides a comprehensive range of oncology diagnostic solutions.
Read more →-NEO
Jan 5, 2026NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NeoGenomics, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management is set to present and engage in a Q&A session on January 13. This event provides a platform for NeoGenomics to highlight its oncology diagnostic solutions and connect with investors.
Read more →-NEO
Dec 30, 2025NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
NeoGenomics has appointed John P. Kenny to its Board of Directors, filling the vacancy left by Alison Hannah. Kenny, a seasoned professional with over 30 years in diagnostics, is expected to leverage his experience to drive growth in cancer testing. His previous roles include leadership positions at Meridian Bioscience and Siemens Healthcare.
Read more →-NEO
Dec 11, 2025NeoGenomics to Present New ctDNA Research at SABCS 2025
NeoGenomics, Inc. will present new findings from its RaDaR 1.0 assay at the 2025 San Antonio Breast Cancer Symposium. The data, derived from the SURVIVE HERoes Phase III trial and the CLEVER study, focus on assessing molecular residual disease and recurrence risk in early breast cancer. The findings aim to enhance the integration of ctDNA testing into routine oncology care.
Read more →Competitive Position
How NEO ranks across every disease it competes inCompetitive Position is a premium feature
See how NEO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial